Clinical trial · Observational
The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
The Function of Pre-Albumin, Retinol Conjugated Protein and Transferrin in Early Malnutrition Detecting and Nutritional Status Dynamic Monitoring for Local Advanced Nasopharyngeal Carcinoma Patients With Chemoradiotherapy
NCT03240835CI-TRIAL-00110758completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma patients with chemoradiotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malnutrition | — | UNRESOLVED | — |
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin and docetaxel | Drug | — | UNRESOLVED |
| IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CCRT±NACT
- description
- Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
- interventionNames
- Drug: cisplatin and docetaxel
- Radiation: IMRT
Primary outcomes (1)
- measure
- changes of PA/RBP/TRSF
- timeFrame
- baseline and during treatment
- description
- to evaluate the changes of PA/RBP/TRSF during the treatment
Secondary outcomes (3)
- measure
- Change of Body weight
- timeFrame
- baseline and during treatment
- description
- to compare the change of weight loss during treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III) * All genders，range from 18～60 years old * Karnofsky performance status(KPS) ≥ 80 * Clinical stage III\~IVb(UICC 8th) * Without significant digestive system disease，nutritional and metabolic diseases or endocrine disease * Without significant cardiac，respiratory，kidney or liver disease * Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy) * white blood cell(WBC) count ≥ 4×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, Hemoglobin(HGB) ≥ 10g/L, platelet(PLT) count ≥ 100×109/L * alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \< 1.5×upper limit of normal(ULN), bilirubin \< 1.5×ULN, alanine aminotransferase (CCR) ≥ 30ml/min * Inform consent form Exclusion Criteria: * Distance metastases * Second malignancy within 5 years * Drug or alcohol addition * Do not have full capacity for civil acts * Active systemic infections * Chronic consumptions * Mental disorder * Pregnancy or lactation * Concurrent immunotherapy or hormone therapy for other diseases * Severe complication, eg, uncontrolled hypertension
References
Publications (0)
Data not yet available
No reference posted for this study.